Yes, yes, I know, placenta cells, but the overwhelming tide of clinical evidence towards successful MOA by stem cells in congenital heart disease keeps building in MSB's favour:
https://healthnews.com/news/stem-cells-from-placenta-save-child-with-congenital-heart-disease/
the FDA has given the okay to stem cells to address blood disorders, as I recently highlighted with Omidubicel. The regulatory and clinical acceptance of stem cells as formal treatments, finally evolving. We are on the threshold and its hard not to get a little excited for patients and science, beyond any financial gain.
Cell Therapy News/Articles, page-16024
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |